Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.

@article{Sulkowski2013AnemiaDT,
  title={Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.},
  author={Mark S Sulkowski and Fred P Poordad and Michael P. Manns and J P Bronowicki and K. Rajender Reddy and S. A. Harrison and Nezam H. Afdhal and Heather L. Sings and Lisa D. Pedicone and Kenneth J. Koury and Vilma Sniukiene and Margaret H Burroughs and Janice K. Albrecht and Clifford A. Brass and I M for the New Paradigm of HCV Therapy Meeting Part Jacobson},
  journal={Hepatology},
  year={2013},
  volume={57 3},
  pages={974-84}
}
UNLABELLED Boceprevir (BOC) added to peginterferon alfa-2b (PegIFN) and ribavirin (RBV) significantly increases sustained virologic response (SVR) rates over PegIFN/RBV alone in previously untreated adults with chronic hepatitis C genotype 1. We evaluate the relationship of incident anemia with triple therapy. A total of 1,097 patients received a 4-week lead-in of PegIFN/RBV followed by: (1) placebo plus PegIFN/RBV for 44 weeks (PR48); (2) BOC plus PegIFN/RBV using response-guided therapy (BOC… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
28 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Management Strategic Healthcare Group and Medical Advisory Panel

  • VHA Pharmacy Benefit
  • Recombinant erythropoietin criteria for use for…
  • 2013
1 Excerpt

Recombinant erythropoietin criteria for use for hepatitis C treatment - related anemia

  • S Zeuzem, P Andreone, S Pol, E Lawitz, M Diago, S Roberts
  • Epoetine beta
  • 2011

Similar Papers

Loading similar papers…